Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

MRNS

Marinus Pharmaceuticals Inc

Nov 08 • 04:00PM ET

0.3454

Dollar change -0.0136
Percentage change -3.79	%

Healthcare • Biotechnology • USA • NASD

Peers: AXSM NBIX ACAD SAGE CYTK SUPN XENE AVDL PTCT VTGN

| Held by: VTI VXF IBB IWC ITOT BTEC BIB IBBQ RFLR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.66	Insider Own	22.98%	Shs Outstand	54.58M	Perf Week	5.34%
Market Cap	18.31M	Forward P/E	-	EPS next Y	-0.70	Insider Trans	-0.24%	Shs Float	42.43M	Perf Month	-79.07%
Income	-149.24M	PEG	-	EPS next Q	-0.41	Inst Own	72.41%	Short Float	8.22%	Perf Quarter	-71.92%
Sales	30.26M	P/S	0.61	EPS this Y	26.21%	Inst Trans	-5.48%	Short Ratio	1.49	Perf Half Y	-74.03%
Book/sh	-0.86	P/B	-	EPS next Y	63.83%	ROA	-103.54%	Short Interest	3.49M	Perf Year	-94.99%
Cash/sh	1.22	P/C	0.28	EPS next 5Y	20.00%	ROE	-2986.55%	52W Range	0.26 - 11.26	Perf YTD	-96.82%
Dividend Est.	-	P/FCF	-	EPS past 5Y	6.04%	ROI	-447.20%	52W High	-96.93%	Beta	1.28
Dividend TTM	-	Quick Ratio	2.15	Sales past 5Y	176.17%	Gross Margin	88.72%	52W Low	32.69%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	2.28	EPS Y/Y TTM	-2191.98%	Oper. Margin	-440.11%	RSI (14)	25.32	Volatility	9.66% 17.05%
Employees	165	Debt/Eq	-	Sales Y/Y TTM	16.56%	Profit Margin	-493.14%	Recom	2.40	Target Price	1.83
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-3.32%	Payout	-	Rel Volume	0.38	Prev Close	0.36
Sales Surprise	-15.89%	EPS Surprise	-6.71%	Sales Q/Q	32.48%	Earnings	Aug 13 BMO	Avg Volume	2.33M	Price	0.35
SMA20	-62.05%	SMA50	-73.97%	SMA200	-90.14%	Trades		Volume	888,719	Change	-3.79%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-24	Upgrade	Oppenheimer	Perform → Outperform	$6
Aug-14-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Apr-16-24	Downgrade	Robert W. Baird	Outperform → Neutral	$20 → $2
Apr-15-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$24 → $3
Aug-11-23	Downgrade	Oppenheimer	Outperform → Perform	$14 → $9
Jan-20-23	Initiated	RBC Capital Mkts	Outperform	$23
Sep-30-20	Initiated	Truist	Buy	$35
Jul-01-20	Reiterated	H.C. Wainwright	Buy	$6 → $9
Jul-01-20	Initiated	Cowen	Outperform
Apr-09-20	Initiated	Craig Hallum	Buy	$4.50
Dec-20-19	Initiated	Oppenheimer	Outperform
Mar-05-19	Resumed	Jefferies	Buy	$3.50 → $10
Feb-27-19	Downgrade	Mizuho	Buy → Neutral	$13 → $5
Feb-06-19	Initiated	Leerink Partners	Outperform	$10
Jul-02-18	Initiated	Cantor Fitzgerald	Overweight	$19
Mar-20-18	Initiated	Mizuho	Buy	$13
Feb-15-18	Initiated	H.C. Wainwright	Buy	$33
Dec-14-17	Initiated	Laidlaw	Buy	$18
Aug-10-16	Reiterated	Jefferies	Buy	$2.50 → $3
Jun-14-16	Downgrade	RBC Capital Mkts	Outperform → Sector Perform

Show Previous Ratings

Oct-25-24 07:28AM	Marinus clinical trial of ganaxolone fails to meet primary endpoint (Clinical Trials Arena) +36.86%
06:35AM	GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar (BioPharma Dive)
Oct-24-24 12:42PM	Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options (Benzinga) -82.49%
08:00AM	Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives (Business Wire)
Oct-18-24 11:17AM	Marinus reports Phase III RAISE trial results for ganaxolone in RSE treatment (Clinical Trials Arena) +6.32%
07:00AM	Loading…
Oct-17-24 07:00AM	Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting (Business Wire)
Oct-15-24 04:57PM	Health Care Roundup: Market Talk (The Wall Street Journal)
04:00PM	Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY Titration Regimens (Business Wire)
Oct-09-24 07:00AM	Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting (Business Wire)
Oct-08-24 04:04PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -5.95%
Oct-03-24 10:14AM	Heres Why PGIM Jennison Health Sciences Fund Reduced its Position in Marinus Pharmaceuticals (MRNS) (Insider Monkey)
Sep-20-24 08:00AM	Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY in TSC at Investor and Analyst Day (Business Wire)
Sep-12-24 08:00AM	Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 (Business Wire)
Sep-10-24 08:00AM	Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference (Business Wire)
Aug-19-24 08:00AM	Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024 (Business Wire) +5.56%
03:39AM	Loading…
Aug-14-24 03:39AM	Q2 2024 Marinus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -6.78%
Aug-13-24 08:10AM	Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:07AM	Marinus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-06-24 08:00AM	3 Biotech Stocks to Sell in August Before They Crash & Burn (InvestorPlace)
Jul-30-24 08:00AM	Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024 (Business Wire)
Jul-24-24 11:28PM	Marinus Pharmaceuticals, Inc. (MRNS): A Good One-Dollar Stock According to Street Analysts? (Insider Monkey)
Jul-22-24 05:45AM	Shareholders of Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS (PR Newswire)
Jul-18-24 07:00AM	Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder (Business Wire)
05:45AM	Shareholders of Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS (PR Newswire)
Jul-15-24 10:45AM	Ovid Therapeutics Inc. (OVID): One of the Best Penny Stocks to Buy Under $1 According to Hedge Funds? (Insider Monkey)
09:35AM	10 Best Penny Stocks to Buy Under $1 (Insider Monkey)
Jun-18-24 04:52AM	Marinus Pharmaceuticals reports data from refractory status epilepticus drug trial (Clinical Trials Arena)
Jun-17-24 07:00AM	Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus (Business Wire)
May-17-24 10:44AM	Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent (MT Newswires)
09:35AM	Loading…
09:35AM	Here's Why Marinus Pharmaceuticals (MRNS) is Poised for a Turnaround After Losing -7.8% in 4 Weeks (Zacks)
07:00AM	Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program (Business Wire)
May-16-24 09:35AM	After Plunging -7.64% in 4 Weeks, Here's Why the Trend Might Reverse for Marinus Pharmaceuticals (MRNS) (Zacks)
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey) -8.92%
11:54AM	MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:30AM	Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:29AM	Marinus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results (Business Wire)
May-07-24 10:18AM	HC Wainwright Adjusts Price Target on Marinus Pharmaceuticals to $11 From $27, Maintains Buy Rating (MT Newswires) +6.08%
May-02-24 08:00AM	Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference (Business Wire)
May-01-24 08:00AM	Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024 (Business Wire)
Apr-16-24 11:46AM	Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study (Zacks) -7.69%
Apr-15-24 12:54PM	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential (InvestorPlace) -82.71%
11:30AM	Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today? (InvestorPlace)
07:00AM	Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results (Business Wire)
Apr-05-24 04:00PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -10.14% +5.13%
Mar-27-24 08:41AM	Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant Review (Business Wire)
Mar-25-24 10:00AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-20-24 10:32AM	Do Options Traders Know Something About Marinus (MRNS) Stock We Don't? (Zacks)
Mar-07-24 01:41PM	Marinus Pharmaceuticals Inc (MRNS) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
11:10AM	Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 07:14AM	Q4 2023 Marinus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-24 05:10PM	Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:24PM	Marinus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-21-24 07:00AM	Marinus Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Feb-20-24 07:00AM	Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 (Business Wire)
Feb-16-24 04:00PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jan-30-24 08:13PM	Marinus Pharmaceuticals Stock (NASDAQ:MRNS): This Drugmaker Boasts a Rare Treatment (TipRanks)
Jan-22-24 09:56AM	Should You Add Marinus (MRNS) Stock to Your Portfolio Now? (Zacks) +5.31%
Jan-17-24 09:55AM	Wall Street Analysts Think Marinus Pharmaceuticals (MRNS) Could Surge 113.01%: Read This Before Placing a Bet (Zacks)
Jan-04-24 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
07:01AM	Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY Net Product Revenue and Provides Business Update (Business Wire)
Dec-29-23 06:45AM	5 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-07-23 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Nov-20-23 04:01PM	Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study (Business Wire)
Nov-14-23 04:05PM	Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire) -5.45%
Nov-09-23 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -14.07%
Nov-08-23 04:32PM	Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.91%
Nov-07-23 07:55AM	Marinus Pharmaceuticals Inc (MRNS) Reports Q3 2023 Financial Results (GuruFocus.com)
07:36AM	Marinus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:01AM	Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results (Business Wire)
07:00AM	Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY (ganaxolone) Oral Suspension CV (Business Wire)
Oct-24-23 07:01AM	Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire)
Oct-11-23 09:55AM	Wall Street Analysts Believe Marinus Pharmaceuticals (MRNS) Could Rally 183.33%: Here's is How to Trade (Zacks)
Oct-06-23 04:00PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -5.43%
Sep-21-23 04:00PM	Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference (Business Wire) -6.18%
Sep-20-23 09:02AM	Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock? (Zacks)
09:01AM	Marinus (MRNS) Up 20% on Financial and Pipeline Updates (Zacks)
Sep-19-23 04:51PM	Marinus Pharmaceuticals extends cash runway, shares surge 16% (Investing.com) +19.88%
08:00AM	Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event (Business Wire)
Sep-12-23 04:00PM	Marinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023 (Business Wire) -5.16%
Sep-06-23 04:01PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -8.46%
Aug-17-23 04:01PM	Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023 (Business Wire) +7.63%
Aug-11-23 04:01PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -13.56%
09:36AM	Twilio upgraded, Sealed Air downgraded: Wall Street's top analyst calls (The Fly)
Aug-10-23 08:40AM	Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.10%
07:34AM	Marinus Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
07:01AM	Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-31-23 12:03PM	Marinus secures European Commission approval for Ztalmy (American City Business Journals) +5.03%
07:01AM	Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder (Business Wire)
Jul-27-23 07:01AM	Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023 (Business Wire)
Jul-25-23 03:48PM	Marinus Pharmaceuticals (NASDAQ:MRNS) shareholders have earned a 71% return over the last year (Simply Wall St.)
Jul-13-23 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jul-03-23 04:23AM	Strength Seen in Marinus Pharmaceuticals (MRNS): Can Its 5.4% Jump Turn into More Strength? (Zacks)
Jun-21-23 04:01PM	Marinus Pharmaceuticals Announces New Method of Use Patent Granted for IV Ganaxolone by USPTO in Status Epilepticus (Business Wire)
Jun-12-23 07:59AM	Institutional investors are Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) biggest bettors and were rewarded after last week's US$149m market cap gain (Simply Wall St.)
Jun-02-23 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
May-26-23 08:10AM	Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder (Business Wire)
May-17-23 04:01PM	Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D. (Business Wire)

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pfanstiel Steven	CFO AND COO	Aug 05 '24	Sale	1.13	4,657	5,262	79,773	Aug 07 04:05 PM
Shafer Christina	CHIEF COMMERCIAL OFFICER	Aug 05 '24	Sale	1.14	3,820	4,355	67,406	Aug 07 04:05 PM
MANNING MARTHA E	SVP, GEN. COUNSEL & CORP. SEC.	Aug 05 '24	Sale	1.13	3,621	4,092	60,263	Aug 07 04:05 PM
Hulihan Joseph	CHIEF MEDICAL OFFICER	Aug 05 '24	Sale	1.13	4,828	5,456	72,725	Aug 07 04:05 PM
Braunstein Scott	CHAIRMAN AND CEO	Aug 05 '24	Sale	1.13	12,145	13,724	298,667	Aug 07 04:05 PM
Braunstein Scott	CHAIRMAN AND CEO	Mar 27 '24	Option Exercise	4.28	50,000	214,000	273,512	Mar 27 11:55 AM
Shafer Christina	CHIEF COMMERCIAL OFFICER	Feb 20 '24	Sale	9.56	2,153	20,583	60,308	Feb 22 04:05 PM
MANNING MARTHA E	SVP, GEN. COUNSEL & CORP. SEC.	Feb 20 '24	Sale	9.57	1,894	18,126	52,966	Feb 22 04:05 PM
Hulihan Joseph	CHIEF MEDICAL OFFICER	Feb 16 '24	Sale	9.98	2,814	28,084	66,635	Feb 21 04:06 PM
Pfanstiel Steven	CFO AND COO	Feb 16 '24	Sale	9.97	3,092	30,827	71,697	Feb 21 04:05 PM
Braunstein Scott	CHAIRMAN AND CEO	Feb 16 '24	Sale	9.94	11,850	117,789	223,512	Feb 21 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRNS

Marinus Pharmaceuticals Inc

Upgrade your FINVIZ experience